Cancer

2012 California County Health Report released by CDPH

County Population Dark Orange is over 900,000, medium orange is 300,000 to 900,000 and lightest yellow is under 300,000 people - credit CDPH.gov report

(Best Syndication News) - The California Department of Public Health has released their County Health Status Profiles 2012 report that assesses the health status of each county throughout the state. The current data analyzed was between 2008 – 2010 and was compared against the Healthy People 2010 National Objectives to determine if the state has met each goal.

The CDPH report saw improvements from the previous report that involved the years of 2005 through 2007. The new report saw around a 14 percent decline in the birthrates of adolescent mothers for the 2008 through 2010 data. There was a 29.4 percent reduction in motor vehicle traffic crash death rates, which was the best improvement overall in the 2012 report. The rates of Gonorrhea infections declined by 25.6 percent. AIDS infections declined by 24.4 percent. Diabetes death rates also showed a decline by 11.1 percent. All cancers including lung, breast, and prostate declined since the 2005 – 2007 report. There also was a reduction in coronary heart disease, and cerebrovascular disease. However, death rates for Alzheimer’s disease and suicide rates increased.

Daily Aspirin Regimen might be beneficial for Preventing Cancer

Aspirin - BSN

(Best Syndication News) - The American Cancer Society has released a new report that suggests aspirin may play a part in reducing the risk for death from cancer. The new information may one day lead to medical professional recommending aspiring for cancer prevention. The report was published online in Nature Reviews Clinical Oncology.

Previous research has suggested that taking a daily aspirin could reduce the risk for colorectal cancer and the recurrence of adenomatous polyps. There is a downfall in taking aspirin for bleeding risk. However, a study of cardiovascular trials found that taking 75-100 mg daily also reduced the cancer risk for all types.

Breast Cancer Cells Transformed into Stem Cells via Radiation Treatments

Radiation Therapy

(Best Syndication News) Researchers say that radiation treatments can turn cancer tumor cells into “treatment resistant breast cancer stem cells.”

Researchers from the UCLA Department of Radiation Oncology at the Jonsson Comprehensive Cancer Center, say that if they can stop the transformation of these cancer cells into stem cells, radiation treatments could be even more effective.

Although half of the tumor cells are killed-off during radiation treatments, some that remain morph into these stem cells that are resistant to the treatments, according to Dr Frank Pajonk, who is also a scientist with the Eli and Edythe Broad Center of Regenerative Medicine at UCLA.

Young Adults who Quit Smoking Improve Respiratory Problems within Weeks

Credit - National Cancer Institute Bill Branson (photographer) - PD

(Best Syndication News) - A research study found that 18 to 24 year olds who quit smoking suffered less respiratory symptoms, with the greatest reduction in coughing.

Karen Calabro, DrPH and Alexander Prokhorov, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, studied college students and analyzed the participants self-reported respiratory symptoms, such as coughing.

The college students participated in a smoking cessation program. The 18-24 year olds had smoked for 1-5 years with an average of 5 – 10 cigarettes daily prior to participation in the study. They had two groups, one that quit smoking successfully for two weeks or more, and the other group who failed to quit smoking. Those that quit smoking showed improvement on respiratory symptoms within weeks of quitting.

Medivation Shares rise after Positive Results from Prostate Drug Trial

alt text

(Best Syndication News) –Medivation, Inc. (NASDAQ: MDVN) shares increased 21.95 percent, up $12.16 to close at $67.57. The share price climbed Wednesday, after of positive results with the Phase 3 AFFIRM trial for a drug to treat prostate cancer. Medivation is working with Japan based Astellas Pharma Inc. (TYO: 4503) on the development of the MDV3100 investigational drug.

Data from the trial showed that MDV3100 provided an average 4.8 month life extension compared to the placebo group. The data will be presented at the 2012 Genitourinary Cancers Symposium in San Francisco, CA this Thursday, February 2.

Syndicate content
Share/Save/Bookmark

      

Post to Facebook

Important: The material on Best Syndication is for informational purposes only and is not meant to be advice. Authors may have or will receive monetary compensation from the company's product/s mentioned. You should always seek professional advice before making any legal, financial or medical decisions and this website cannot substitute or replace any trained professional consultation.
Use of this site means that you agree to our TERMS OF SERVICE

Advertise On This Site
Copyright © 2006-2015 By Best Syndication All Rights Reserved